Thursday 6 | October  2016

 
   LSBC EVENTS
Access to Innovation
November 2 & 3, 2016
Vancouver, BC
 

Hosted for its second year, LifeSciences BC's Access to Innovation Conference will bring together health and life sciences stakeholders to present, discuss and deliver meaningful ways to culitivate collaboration, develop and deliver innovation, while improving outcomes and saving healthcare cost.
 
Keynote Speakers: Hon. Dr. Andrew Wilkinson, Minister of Advanced Education & Hon. Amrik Virk, Minister of Technology, Innovation & Citizens' Services

Confirmed Presenters: Dr. Jane Aubin, Dr. Robert McMaster, Dr. Brendan Byrne, Dr. David Castle, Dr. Heather Davidson, Dr. Bettina Hamelin, Dr. Simon Sutcliffe, Dr. Gavin Stuart, Dr. Sue Collier and Dr. Leslie Alexander, CEO & President, Life Sciences Washington 

 

  MEMBER NEWS
 AURINIA ANNOUNCES THAT VOCLOSPORIN ACHIEVES PRIMARY AND ALL PRE-SPECIFIED SECONDARY ENDPOINTS IN ITS PHASE IIb AURA-LV STUDY FOR LUPUS NEPHRITIS (LN)

 Victoria, British Columbia -SEPTEMBER 29th, 2016: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") a clinical stage biopharmaceutical company focused on the global immunology market, today announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group.
 
Precision NanoSystems New Headquarters Designed to Enhance Product and Service Offerings to Customers Developing Novel Nanomedicines

VANCOUVER, British Columbia, Oct. 6, 2016 /PRNewswire/ - Precision NanoSystems (PNI), a biotechnology company pioneering innovative manufacturing solutions for novel nanoparticles used to investigate or treat disease, today announced the opening of its new corporate headquarters in Vancouver, British Columbia.
Vancouver-based MSI raises US$30 million investment from Quark Venture Inc. to advance treatment for patients suffering with Major Depressive Disorder

Vancouver, BC - October 6, 2016: Today, Quark Venture Inc., a venture capital company, announced a US$30 million investment in MSI (MSI Methylation Sciences Inc.), a clinical-stage pharmaceutical company, that will enable MSI to advance development of an oral, small molecule therapy for adjunctive treatment of Major Depressive Disorder (MDD). The investment is through Quark Venture's Global Health Sciences Venture Fund.
  INDUSTRY NEWS
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor Insmed expects to advance compound into a phase 2 dose-ranging study in non-cystic fibrosis bronchiectasis in 2017

BRIDGEWATER, N.J. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known as cathepsin C). DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases (NSPs), which play a key role in pulmonary diseases such as non-cystic fibrosis bronchiectasis (non-CF bronchiectasis). 
 Merck, NewLink nab up to $76M BARDA contract to back Ebola vaccine
 
  IN THIS ISSUE
PLATINUM SPONSORS
GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

MSFHR
  HEALTH NEWS
 
Oct 2516 | University of Glasgow | is often necessary to identify unfamiliar people by comparing face images: for example a CCTV image to a mugshot, or a passport photograph to a traveller.
 
  JOB LINKS
Life Science Career Opportunities
   NEW COST SAVINGS FOR MEMBERS
Did you know about our Business Solutions Program? Through our vendor partners, LifeSciences BC members can benefit from significant savings on a number of business services. For the full list of cost savings for members, please see: http://www.lifesciencesbc.ca/membership/members-lsbc-business-solutions-program/
Introducing the UPSĀ® Members Benefit Program for Life Sciences BC Members
 
Take advantage of the UPS Members Benefit Program and save on a variety of UPS services! You'll receive 30% off small package shipments within Canada, to the U.S. and to worldwide destinations, 25% off imports into Canada, discounts starting at 70% off freight shipments and more.  
  
Save on office supplies and more with Grand & Toy

Through your Life Sciences BC membership, you can save 10%-20% off the web price of wide range of office supplies from Grand & Toy! Plus, there is no charge for next-business-day delivery on orders over $50 to most Canadian locations. (Some conditions apply.) 
 
Corporate discounts & group rates at The Listel Hotel

The Listel Hotel, a four star boutique hotel, is known for its enthusiastic service and commitment to high design and guest comfort. This intimate Robson street hotel boasts a perfect location with an award-winning restaurant Forage and gastro-pub Timber.
 
Suite 580 1285 West Broadway, 
Vancouver, BC V6H 3X8
604-669-9909
info@lifesciencesbc.ca